Author Bio
Adria Cimino grew up with her nose in a book and a love of storytelling. By a twist of fate, she started her career writing about biotech in Boston and discovered that each company is the source of many fascinating stories. Prior to joining The Fool as a contract writer focused on healthcare and consumer goods, Adria covered the stock market for Bloomberg News in Paris. When she’s not analyzing companies, she can be found writing fiction or trying to speak French as well as her 9-year-old daughter. Follow @adria in paris
Novavax (NASDAQ:NVAX) to market with a coronavirus vaccine. The U.S. Food and Drug Administration (FDA) authorized Moderna s candidate in December. Novavax expects to report U.S. phase 3 trial data in the coming weeks and complete an Emergency Use Authorization (EUA) request this quarter.